论文部分内容阅读
目前随着晚期结直肠癌分子生物学研究的不断深入,表皮生长因子受体(EGFR)单抗在转移性结直肠癌的治疗中变得尤为重要,尤其是西妥昔单抗和帕尼单抗,在标准化疗方案失败的患者中具有很高的疗效。大量临床试验表明,在晚期结直肠癌的治疗中,无论一线、二线抑或是转化化疗,标准化疗方案联合EGFR单抗靶向药物治疗的疗效均优于单纯化疗。为了进一步筛检EGFR单抗疗效的有效性,对相关基因研究的结果为此提供了依据,例如EGFR基因拷贝量的多少,及其下游通路的KRAS,BRAF,PIK3CA基因的状态等。本文结合最新报道,就EGFR单抗治疗转移性结直肠癌的疗效及预测因子做一综述。
At present, with the further research of molecular biology of advanced colorectal cancer, epidermal growth factor receptor (EGFR) monoclonal antibody has become particularly important in the treatment of metastatic colorectal cancer, especially cetuximab and panitum Resistant, with high efficacy in patients who have failed standard chemotherapy regimens. A large number of clinical trials show that in the treatment of advanced colorectal cancer, regardless of first-line, second-line or conversion chemotherapy, the standard chemotherapy combined with EGFR monoclonal antibody targeted therapies are better than chemotherapy alone. In order to further screen the efficacy of EGFR monoclonal antibody, the results of related gene research provide a basis for this, such as EGFR gene copy number, and its downstream pathway KRAS, BRAF, PIK3CA gene status. This article combined with the latest report on the EGFR monoclonal antibody treatment of metastatic colorectal cancer efficacy and predictors are reviewed.